PD-L1, STAT3, IL6, and EGFR Immunoexpressions in High-Grade Osteosarcoma.

IF 16.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY Accounts of Chemical Research Pub Date : 2024-02-23 eCollection Date: 2024-01-01 DOI:10.1155/2024/9036225

Nayla Rahmadiani, Eviana Norahmawati, Agustina Tri Endharti, Ailen Oktaviana Hambalie, Satria Pandu Persada Isma

{"title":"PD-L1, STAT3, IL6, and EGFR Immunoexpressions in High-Grade Osteosarcoma.","authors":"Nayla Rahmadiani, Eviana Norahmawati, Agustina Tri Endharti, Ailen Oktaviana Hambalie, Satria Pandu Persada Isma","doi":"10.1155/2024/9036225","DOIUrl":null,"url":null,"abstract":"Introduction: Immunotherapy has been widely used in the treatment of various malignancies with satisfactory results. One of the agents for immunotherapy is an inhibitor of programmed cell death-1 and its ligands (PD-1 and PD-L1). However, attempts at utilizing PD-1/PD-L1 immunotherapy in osteosarcoma have not yielded favorable results. This may be due to differences in PD-L1 regulation and the immune landscape in osteosarcoma, as the mechanism is still poorly understood. Therefore, elucidating PD-L1 regulation in osteosarcoma is paramount in order to improve treatment results using immunotherapy.Methods: This is a cross-sectional study conducted in the Department of Anatomical Pathology of Saiful Anwar Hospital using 33 paraffin blocks of confirmed cases of osteosarcoma. Immunohistochemical staining using PD-L1, STAT3, IL6, and EGFR was performed. Statistical analyses were subsequently performed on the immunoexpression data of these antibodies.Results: PD-L1, STAT3, IL6, and EGFR expressions were found in 6 (18.2%), 6 (18.2%), 28 (84.8%), and 30 (90.9%) cases, respectively. There were significant correlations between PD-L1 and STAT3 (r = 0.620, p=<0.001), PD-L1 and EGFR (r = 0.449, p=0.009), as well as STAT3 and EGFR (r = 0.351, p=0.045).Conclusion: The existence of a correlation between PD-L1, STAT3, and EGFR indicates the potential role of STAT3 and EGFR in PD-L1 regulation in osteosarcoma, which may become the basis for targeted therapy.","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10907101/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2024/9036225","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Immunotherapy has been widely used in the treatment of various malignancies with satisfactory results. One of the agents for immunotherapy is an inhibitor of programmed cell death-1 and its ligands (PD-1 and PD-L1). However, attempts at utilizing PD-1/PD-L1 immunotherapy in osteosarcoma have not yielded favorable results. This may be due to differences in PD-L1 regulation and the immune landscape in osteosarcoma, as the mechanism is still poorly understood. Therefore, elucidating PD-L1 regulation in osteosarcoma is paramount in order to improve treatment results using immunotherapy.

Methods: This is a cross-sectional study conducted in the Department of Anatomical Pathology of Saiful Anwar Hospital using 33 paraffin blocks of confirmed cases of osteosarcoma. Immunohistochemical staining using PD-L1, STAT3, IL6, and EGFR was performed. Statistical analyses were subsequently performed on the immunoexpression data of these antibodies.

Results: PD-L1, STAT3, IL6, and EGFR expressions were found in 6 (18.2%), 6 (18.2%), 28 (84.8%), and 30 (90.9%) cases, respectively. There were significant correlations between PD-L1 and STAT3 (r = 0.620, p=<0.001), PD-L1 and EGFR (r = 0.449, p=0.009), as well as STAT3 and EGFR (r = 0.351, p=0.045).

Conclusion: The existence of a correlation between PD-L1, STAT3, and EGFR indicates the potential role of STAT3 and EGFR in PD-L1 regulation in osteosarcoma, which may become the basis for targeted therapy.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

高级别骨肉瘤中的 PD-L1、STAT3、IL6 和表皮生长因子受体免疫表达

简介免疫疗法已被广泛用于治疗各种恶性肿瘤，并取得了令人满意的效果。免疫疗法的药物之一是程序性细胞死亡-1 及其配体（PD-1 和 PD-L1）的抑制剂。然而，在骨肉瘤中尝试使用PD-1/PD-L1免疫疗法的结果并不理想。这可能是由于骨肉瘤中PD-L1调控和免疫格局的差异造成的，因为对其机制还不甚了解。因此，阐明骨肉瘤中的PD-L1调控对于提高免疫疗法的治疗效果至关重要：这是一项在赛义夫-安瓦尔医院解剖病理部进行的横断面研究，使用了 33 个骨肉瘤确诊病例的石蜡块。对 PD-L1、STAT3、IL6 和表皮生长因子受体进行了免疫组化染色。随后对这些抗体的免疫表达数据进行了统计分析：结果：PD-L1、STAT3、IL6 和表皮生长因子受体分别在 6 例（18.2%）、6 例（18.2%）、28 例（84.8%）和 30 例（90.9%）病例中表达。PD-L1与STAT3（r=0.620，p=r=0.449，p=0.009）以及STAT3与表皮生长因子受体（r=0.351，p=0.045）之间存在明显相关性：结论：PD-L1、STAT3和表皮生长因子受体之间存在相关性，表明STAT3和表皮生长因子受体在骨肉瘤PD-L1调控中的潜在作用，这可能成为靶向治疗的基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.